GlassScriptPhysician profile
Ronald David Nelson
NPI 1629076328
$2,846.99
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $146 · 2021: $68.20 · 2022: $682 · 2023: $491 · 2024: $17.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $653.93 | 2019-2023 | |
| Pfizer INC. | $330.04 | 2019-2023 | |
| Boston Scientific Corporation | $263.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $200.35 | 2019-2022 | |
| Covidien LP | $160.76 | 2019 | |
| Amarin Pharma, INC. | $145.75 | 2019-2020 | |
| Amgen INC. | $114.61 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $113.31 | 2019 | |
| Abiomed | $109.54 | 2019 | |
| Medtronic, INC. | $101.49 | 2022 | |
| Medtronic Vascular, INC. | $93.10 | 2019 | |
| Heartflow, INC. | $85.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.33 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $46.67 | 2022-2023 | Verquvo |
| Kls-Martin L.P. | $37.02 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $33.71 | 2023 | |
| United Therapeutics Corporation | $32.17 | 2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $30.78 | 2023 | Farxiga, Andexxa |
| Bayer Healthcare Pharmaceuticals INC. | $30.18 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $27.99 | 2023 | Uptravi, Opsumit |
| Edwards Lifesciences Corporation | $26.11 | 2019 | |
| Chiesi USA, INC. | $25.21 | 2023 | Kengreal, Cleviprex |
| Angiodynamics, INC. | $21.34 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.02 | 2019-2021 | |
| Cardiovascular Systems INC. | $18.75 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.03 | 2023 | Inpefa |
| Nuwellis, INC. | $16.60 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.